var data={"title":"Histopathology and molecular pathogenesis of medulloblastoma","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Histopathology and molecular pathogenesis of medulloblastoma</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/contributors\" class=\"contributor contributor_credentials\">Scott L Pomeroy, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/contributors\" class=\"contributor contributor_credentials\">Jay S Loeffler, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/contributors\" class=\"contributor contributor_credentials\">Patrick Y Wen, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/contributors\" class=\"contributor contributor_credentials\">Amar Gajjar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/contributors\" class=\"contributor contributor_credentials\">April F Eichler, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 11, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Medulloblastomas are the most common malignant brain tumor of childhood and occur exclusively in the cerebellum. Histologically, they are highly cellular tumors with dark staining, round or oval nuclei. On a molecular level, medulloblastomas are heterogeneous and can be divided into four distinct subgroups with divergent tumor cell histology, genetics, clinical behavior, and patient outcomes. </p><p>The histopathology and molecular pathogenesis of medulloblastoma will be reviewed here. The clinical presentation, diagnosis, and treatment of medulloblastoma in children and adults, prognosis, and the delayed complications in survivors are discussed separately. (See <a href=\"topic.htm?path=clinical-presentation-diagnosis-and-risk-stratification-of-medulloblastoma\" class=\"medical medical_review\">&quot;Clinical presentation, diagnosis, and risk stratification of medulloblastoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>At surgery, medulloblastomas are soft, friable tumors, often with necrosis. They are highly cellular tumors with abundant dark staining, round or oval nuclei, and little cytoplasmic differentiation. The spectrum of histopathologic appearance ranges from tumors with extensive nodularity to those with large <span class=\"nowrap\">cell/anaplastic</span> features. The clinical outcome appears to be worse with increasing grade and extent of anaplasia [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/1\" class=\"abstract_t\">1</a>]. Mitoses are often abundant, and neuroblastic Homer Wright rosettes can be found in up to 40 percent of cases [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p>Immunohistochemical studies most often demonstrate the expression of the neuronal markers synaptophysin and neuron specific enolase, and nestin, a marker of primitive neuroepithelial cells, consistent with their presumed origin from neuronal progenitors in the cerebellum [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/4\" class=\"abstract_t\">4</a>]. Some medulloblastoma subtypes express markers specific for cerebellar granule cells [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/5,6\" class=\"abstract_t\">5,6</a>], supporting the conclusion that they arise most often by oncogenic transformation of cerebellar granule cell progenitors; others express markers suggesting that they arise from multipotential progenitor cells from earlier stages of neural development. Nuclear beta-catenin staining is present in most Wingless-related integration site (Wnt) pathway tumors, and p53 immunostaining can be performed to identify tumors with <em>TP53</em> mutations. (See <a href=\"#H4480322\" class=\"local\">'Molecular subgroups'</a> below.)</p><p>Several histologic variants of medulloblastoma have been described (<a href=\"image.htm?imageKey=ONC%2F88305\" class=\"graphic graphic_figure graphicRef88305 \">figure 1</a> and <a href=\"image.htm?imageKey=NEURO%2F109467\" class=\"graphic graphic_table graphicRef109467 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/7\" class=\"abstract_t\">7</a>]. The desmoplastic variant has abundant collagen and reticulin in the interstitial spaces as well as reticulin free &quot;pale islands&quot; [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/3\" class=\"abstract_t\">3</a>]. This variant is associated with mutations in the patched-1 (<em>PTCH1</em>) gene on chromosome 9 and may have a better prognosis [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/8\" class=\"abstract_t\">8</a>]. A second variant, the large <span class=\"nowrap\">cell/anaplastic</span> (LCA) medulloblastoma, is characterized by cerebrospinal fluid dissemination and a more aggressive clinical course [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/9\" class=\"abstract_t\">9</a>]. The LCA variant is most commonly associated with the group 3 molecular subtype in children and with group 4 tumors in adults. (See <a href=\"#H4480330\" class=\"local\">'Group 3'</a> below and <a href=\"#H4480338\" class=\"local\">'Group 4'</a> below.)</p><p>The prognostic implications of these histopathologic variants are discussed separately. (See <a href=\"topic.htm?path=clinical-presentation-diagnosis-and-risk-stratification-of-medulloblastoma#H3172586\" class=\"medical medical_review\">&quot;Clinical presentation, diagnosis, and risk stratification of medulloblastoma&quot;, section on 'Histopathology'</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">MOLECULAR PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Previously, medulloblastomas were thought to represent a subset of primitive neuroectodermal tumor (PNET) of the posterior fossa [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/10\" class=\"abstract_t\">10</a>]. However, gene expression profiling has shown that medulloblastomas are distinct from other PNET tumors [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/11\" class=\"abstract_t\">11</a>]. In addition, insights derived from medulloblastomas that occur in association with two genetic syndromes, Gorlin syndrome and Turcot syndrome, combined with gene expression profiling of sporadic tumors, have led to the recognition that medulloblastoma can be divided into four distinct molecular subgroups (<a href=\"image.htm?imageKey=NEURO%2F87770\" class=\"graphic graphic_figure graphicRef87770 \">figure 2</a>). </p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Genetic predisposition</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 2 to 5 percent of children with medulloblastomas have inherited disorders with germline mutations of specific genes that predispose to the development of medulloblastoma [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/12,13\" class=\"abstract_t\">12,13</a>]. An understanding of the molecular pathways involved in these genetic syndromes has provided insights into the pathogenesis of sporadic medulloblastomas as well.</p><p class=\"headingAnchor\" id=\"H4480307\"><span class=\"h3\">Gorlin syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nevoid basal cell carcinoma syndrome (NBCCS, also called Gorlin syndrome) is the most common genetic syndrome associated with medulloblastoma. It is an autosomal dominant disease due to germline mutations in the patched-1 (<em>PTCH1</em>) gene on chromosome 9, a key component in the sonic hedgehog (SHH) pathway. Less commonly, NBCCS may be due to germline mutations in the suppressor of fused (<em>SUFU</em>) gene [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/14\" class=\"abstract_t\">14</a>]. The mechanism through which <em>PTCH1</em> mutations lead to overactivation of the SHH pathway in NBCCS is discussed separately. (See <a href=\"topic.htm?path=nevoid-basal-cell-carcinoma-syndrome#H2\" class=\"medical medical_review\">&quot;Nevoid basal cell carcinoma syndrome&quot;, section on 'Molecular genetics'</a>.) &#160; </p><p>During normal cerebellar development, SHH is produced by Purkinje neurons and stimulates growth and migration of granule neuron precursor cells. Overactive SHH signaling plays a key role in the pathogenesis of a subset of sporadic medulloblastomas as well as those associated with NBCCS. The first sporadic mouse model of medulloblastoma was created by germline deletion of one <em>PTCH1</em> allele [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"#H5\" class=\"local\">'SHH pathway'</a> below.)</p><p>Medulloblastoma develops in 3 to 5 percent of patients with NBCCS, typically by the age of three, and may be the earliest overt manifestation of the syndrome [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/16\" class=\"abstract_t\">16</a>]. Importantly, <em>SUFU </em>mutation-associated NBCCS appears to be associated with a much higher risk of medulloblastoma than that of <em>PTCH1</em>-associated NBCCS [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/14\" class=\"abstract_t\">14</a>]. Tumors often show desmoplastic histologic features. Other tumors associated with NBCCS include multiple basal cell cancers and ovarian fibromas. The clinical manifestations of NBCCS are discussed separately. (See <a href=\"topic.htm?path=nevoid-basal-cell-carcinoma-syndrome\" class=\"medical medical_review\">&quot;Nevoid basal cell carcinoma syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4480314\"><span class=\"h3\">Turcot syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Turcot syndrome is a historic term that originally described an association between brain tumors (primarily medulloblastomas and gliomas) and two different forms of inherited colonic polyposis, familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/17\" class=\"abstract_t\">17</a>]. It is now clear that medulloblastomas are associated with FAP and not HNPCC. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis#H625428197\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of familial adenomatous polyposis&quot;, section on 'Turcot syndrome'</a>.)</p><p>FAP is an autosomal dominant condition caused by inactivating mutations in the adenomatous polyposis coli (<em>APC)</em> gene on chromosome 5. A germline mutation in one <em>APC</em> allele plus a &quot;second hit&quot; deletion of the other allele results in loss of all functional APC protein and a high propensity for colonic polyp formation. The genetics of FAP are discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis#H547090028\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of familial adenomatous polyposis&quot;, section on 'Genetics'</a>.)</p><p>APC is part of a protein complex in the Wingless-related integration site (Wnt) signaling pathway, which is a network of proteins that controls cell proliferation and differentiation during development and healing. Loss of APC, as occurs in FAP, ultimately leads to excessive intranuclear accumulation of beta-catenin, an intracellular protein involved in the pathogenesis of medulloblastoma. Deregulation of the Wnt pathway by somatic mutations in the beta-catenin gene, <em>CTNNB1</em>, is also recognized in a subset of sporadic medulloblastomas. (See <a href=\"#H6\" class=\"local\">'Wnt pathway'</a> below.)</p><p>Medulloblastoma develops in less than 1 percent of patients with FAP, but the risk may not be uniform across all families [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/17,18\" class=\"abstract_t\">17,18</a>]. It appears to be highest in those with mutations in segment 2 of the <em>APC</em> gene [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/19\" class=\"abstract_t\">19</a>]. If this observation is confirmed, patients with mutations in this portion of the <em>APC</em> gene might be candidates for genetic counseling or surveillance.</p><p class=\"headingAnchor\" id=\"H4480322\"><span class=\"h2\">Molecular subgroups</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gene expression profiling using tumor tissue microarrays is an evolving approach to molecular classification of medulloblastoma. Several large studies using medulloblastoma samples pooled from multiple centers have attempted to subclassify medulloblastoma based on genome-wide DNA copy number, mRNA expression profiles, and somatic copy number aberrations [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/20-25\" class=\"abstract_t\">20-25</a>]. Several different classifications have been generated; the most widely accepted separates medulloblastoma into four distinct molecular subgroups: SHH, Wnt, group 3, and group 4 [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/26\" class=\"abstract_t\">26</a>]. Somatic mutations identified through whole genome or whole exome sequencing also appear to segregate into these subgroups [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/27-29\" class=\"abstract_t\">27-29</a>]. </p><p>These subgroups have divergent tumor cell histology, genetics, clinical behavior, and patient outcomes (<a href=\"image.htm?imageKey=NEURO%2F87770\" class=\"graphic graphic_figure graphicRef87770 \">figure 2</a>) and are recognized genetically defined diagnoses in the World Health Organization (WHO) classification system (<a href=\"image.htm?imageKey=NEURO%2F109467\" class=\"graphic graphic_table graphicRef109467 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/20-22,27,30\" class=\"abstract_t\">20-22,27,30</a>]. In the future, molecular subgroups are likely to play an increasingly important role in the design of clinical trials and development of new therapies [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/31\" class=\"abstract_t\">31</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">SHH pathway</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The granule cell progenitors can be stimulated to proliferate by the cerebellar Purkinje cells in a process that is mediated by SHH protein. Overactive signaling by SHH appears to have a proliferative effect on these cells and thus contributes to the pathogenesis of medulloblastoma in several ways:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>SHH binds to its receptor, PTCH1. In the absence of binding to SHH, PTCH1 normally interacts with Smoothened (SMO), blocking the activation of a number of downstream transcription pathways. Overactive signaling by SHH prevents the inhibition of these pathways by PTCH1 (<a href=\"image.htm?imageKey=ONC%2F69105\" class=\"graphic graphic_figure graphicRef69105 \">figure 3</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>SHH appears to upregulate the <em>MYCN</em> gene. N-myc, the protein product of <em>MYCN,</em> has multiple effects in the cell cycle, and degradation of N-myc appears necessary for the granule cell progenitors to exit the cell cycle.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In some cases, SHH signaling is enhanced by loss of function of the tumor suppressor gene <em>GNAS</em>, which encodes the G protein alpha subunit<sub> </sub>[<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/32\" class=\"abstract_t\">32</a>]. The alpha subunit is enriched in granule neuron precursors in the cerebellum and suppresses SHH signaling through cyclic adenosine monophosphate (cAMP)-dependent pathway regulation, among other functions. The importance of this pathway is further supported by the finding of medulloblastoma in an infant with a homozygous nonsense mutation within the <em>GNAS</em> coding region [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/33\" class=\"abstract_t\">33</a>].</p><p/><p>Activation of the SHH pathway can occur in the absence of germline or somatic mutations to <em>PTCH1</em> in patients with medulloblastoma. These include truncating mutations of <em>PTCH2</em>, a homologue of <em>PTCH1</em> that is localized to the short arm of chromosome 1 [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/34\" class=\"abstract_t\">34</a>]; both somatic and germline mutations in the <em>SUFU</em>, another gene involved in the SHH pathway that is localized to chromosome 10q [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/35\" class=\"abstract_t\">35</a>]; and mutations in <em>GLI3</em>, a downstream component of the SHH pathway, located on chromosome 7p [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/36\" class=\"abstract_t\">36</a>]. A subset of these tumors have mutations in isocitrate dehydrogenase type 1 (<em>IDH1</em>) and exhibit a hypermethylation phenotype [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/37\" class=\"abstract_t\">37</a>]. Approximately 20 percent harbor mutations that target histone acetyltransferase (HAT) complexes.</p><p>Alterations in the SHH pathway are present in approximately 30 percent of medulloblastomas. As in the Gorlin syndrome, these medulloblastomas are often desmoplastic [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/35\" class=\"abstract_t\">35</a>]. (See <a href=\"#H4480307\" class=\"local\">'Gorlin syndrome'</a> above.)</p><p><em>TP53 </em>mutations have been identified in 10 to 20 percent of SHH tumors and are important biologically and prognostically [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/38\" class=\"abstract_t\">38</a>].<em> TP53</em>-mutant SHH tumors often harbor high-level <em>MYC</em> amplification and chromosomal instability [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/38,39\" class=\"abstract_t\">38,39</a>]. Unlike <em>TP53</em> wildtype SHH tumors, which are overrepresented in infants and adults with medulloblastoma [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/21\" class=\"abstract_t\">21</a>], <em>TP53-</em>mutant SHH tumors have a peak incidence in adolescence [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/38\" class=\"abstract_t\">38</a>]. Patients with <em>TP53</em>-mutant SHH tumors have much worse survival compared with those with <em>TP53</em> wildtype SHH tumors, with a five-year overall survival of approximately 40 percent. A significant number harbor germline mutations in <em>TP53</em>, indicative of the Li-Fraumeni cancer predisposition syndrome. (See <a href=\"topic.htm?path=li-fraumeni-syndrome\" class=\"medical medical_review\">&quot;Li-Fraumeni syndrome&quot;</a>.) </p><p>SHH tumors with wild-type <em>TP53</em> are overrepresented in infants and adults with medulloblastoma [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/21\" class=\"abstract_t\">21</a>]. Patients with these tumors have an intermediate prognosis, with overall survival rates of approximately 80 percent.</p><p>Antagonists of the SHH pathway are an active area of investigation, although early enthusiasm has been dampened by acquired resistance and early relapse with monotherapy [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/40,41\" class=\"abstract_t\">40,41</a>]. In addition, SHH antagonist therapy causes bony abnormalities in children and can only be given to patients who have completed skeletal growth or are skeletally mature.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Wnt pathway</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Wnt protein binds to its receptor, Frizzled, and this interaction destabilizes a multiprotein complex that includes the adenomatous polyposis coli (APC) protein. This in turn initiates a sequence of events that can activate various transcription factors, which are important in the pathogenesis of medulloblastoma. Loss of chromosome 6 and somatic mutations of <em>CTNNB1</em> that promote stabilization and nuclear localization of beta-catenin are present in approximately 85 to 90 percent of Wnt pathway tumors [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/37\" class=\"abstract_t\">37</a>]. <em>TP53</em> mutations are present in approximately 15 percent but do not carry the same prognostic significance as in SHH pathway tumors [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/38\" class=\"abstract_t\">38</a>].</p><p>Wnt signaling mutations have been identified in patients with Turcot syndrome and in approximately 10 percent of patients with sporadic medulloblastomas, making it the least common subgroup [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/26\" class=\"abstract_t\">26</a>]. Wnt tumors are seen in children and adults but rarely infants. They metastasize infrequently and are associated with the most favorable prognosis out of the four subgroups, with a five-year survival of over 95 percent [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/21,42\" class=\"abstract_t\">21,42</a>]. (See <a href=\"#H4480314\" class=\"local\">'Turcot syndrome'</a> above.) </p><p class=\"headingAnchor\" id=\"H4480330\"><span class=\"h3\">Group 3</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>High-level amplification of the <em>MYC</em> proto-oncogene is characteristic of group 3 medulloblastomas, and almost all cases exhibit aberrant <em>MYC </em>expression [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/20,23\" class=\"abstract_t\">20,23</a>]. Group 3 tumors are also characterized by high levels of genomic instability. In approximately one third of group 3 tumors, somatic genomic rearrangements have been described that lead to activation of growth factor independence 1 (<em>GFI1</em>) or <em>GFI1B</em> proto-oncogenes, a process termed &quot;enhancer hijacking&quot; [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/37,43\" class=\"abstract_t\">37,43</a>]. Group 3 is also enriched in alterations in the Notch and transforming growth factor-beta (TGF-beta) signaling pathways as well as hotspot insertions targeting <em>KBTBD4</em> [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/37\" class=\"abstract_t\">37</a>].</p><p>Group 3 tumors comprise approximately 25 percent of sporadic medulloblastomas and are seen primarily in children [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/26,42\" class=\"abstract_t\">26,42</a>]. They are enriched for the large cell anaplastic (LCA) histologic variant and are frequently metastatic at the time of diagnosis. Group 3 tumors have the worst prognosis of the four subgroups, with an increased likelihood of metastatic recurrence [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/44\" class=\"abstract_t\">44</a>] and a five-year survival of approximately 50 percent [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/21\" class=\"abstract_t\">21</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H4480338\"><span class=\"h3\">Group 4</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many group 4 tumors exhibit amplification of the proto-oncogenes <em>MYCN</em> and cyclin-dependent kinase 6 (<em>CDK6)</em>. Characteristic cytogenetic abnormalities include isochromosome 17q and loss of one copy of the X chromosome (in females). A small proportion of group 4 tumors have <em>GFI1 </em>or <em>GFI1B</em> activation due to somatic structural variants, as described more commonly in group 3 tumors [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/37,43\" class=\"abstract_t\">37,43</a>]. More commonly, group 4 tumors exhibit structural variants in <em>SNCAIP</em> associated with enhancer hijacking of the <em>PRDM6</em> gene [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/37\" class=\"abstract_t\">37</a>]. Hotspot insertions targeting <em>KBTBD4</em> are also common [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/37\" class=\"abstract_t\">37</a>]. </p><p>Approximately 35 percent of sporadic medulloblastomas fall into this subgroup [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/26\" class=\"abstract_t\">26</a>]. Tumors usually exhibit classic histology. There is a strong male predominance (3:1) and a peak incidence in adolescence. The prognosis in children is similar to the SHH subgroup, with a 35 to 40 percent rate of metastasis at diagnosis and five-year survival of approximately 75 percent [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/26\" class=\"abstract_t\">26</a>]. By contrast, the prognosis of group 4 tumors in adults appears to be significantly worse than that of SHH tumors, with a high incidence of high-risk disease and large <span class=\"nowrap\">cell/anaplastic</span> histology [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/42\" class=\"abstract_t\">42</a>].</p><p class=\"headingAnchor\" id=\"H4480625\"><span class=\"h1\">CELL OF ORIGIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is evidence that the cell of origin may also differ according to molecular subgroup, and putative cells of origin have been identified for three of the four subgroups.</p><p>Available data suggest that sonic hedgehog (SHH) medulloblastomas arise from cerebellar granule neuron precursors of the external granule cell layer (EGL) or cochlear nuclei [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/45,46\" class=\"abstract_t\">45,46</a>], or from multipotent progenitors of the subventricular zone (SVZ) [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/47-49\" class=\"abstract_t\">47-49</a>]. Group 3 tumors also appear to arise from cerebellar granule neuron precursors in the EGL or neural stem cells in the SVZ [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/50,51\" class=\"abstract_t\">50,51</a>]. Progression to medulloblastoma is thought to occur when these granule cell progenitors are subject to continued stimulation or there is a failure of these cells to exit the cell cycle.</p><p>Wingless-related integration site (Wnt) subgroup tumors appear to arise in lower rhombic lip progenitors of the dorsal brainstem [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/52\" class=\"abstract_t\">52</a>]. </p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">GENETIC REGULATION OF METASTASIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Medulloblastomas have a tendency to disseminate throughout the central nervous system early in the course of the disease, and metastatic disease is associated with a poor outcome. Studies of matched primary and recurrent tissue samples show that the four-group molecular signature is retained at the time of recurrence [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/44\" class=\"abstract_t\">44</a>]. Group 3 and 4 tumors in particularly have a higher likelihood of metastatic recurrence compared with sonic hedgehog (SHH) pathway tumors, which are more likely to recur locally. (See <a href=\"topic.htm?path=clinical-presentation-diagnosis-and-risk-stratification-of-medulloblastoma\" class=\"medical medical_review\">&quot;Clinical presentation, diagnosis, and risk stratification of medulloblastoma&quot;</a>.)</p><p>In one report of 23 primary medulloblastomas, of which 10 were metastatic and 13 nonmetastatic, the platelet-derived growth factor receptor (PDGFR)-alpha was upregulated and overexpressed in the metastatic tumors and associated with migratory behavior [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/53\" class=\"abstract_t\">53</a>]. Cell culture experiments with medulloblastoma cell lines demonstrated that overexpression of PDGFR-alpha increased the phosphorylation and upregulation of downstream <span class=\"nowrap\">Ras/mitogen-activated</span> protein (MAP) kinase signal transduction pathways, while inhibition of these MAP kinases prevented PDGFR-alpha-stimulated migration in a cell culture assay. Further analysis revealed upregulated expression of PDGFR-beta in metastatic medulloblastomas, indicating a role of several PDGFR isoforms in medulloblastoma biology [<a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/54\" class=\"abstract_t\">54</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Medulloblastomas are highly cellular tumors presumed to arise from neuronal precursors in the cerebellum. (See <a href=\"#H2\" class=\"local\">'Histopathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In approximately 5 percent of cases, medulloblastomas have been associated with one of two inherited disorders that are providing insight into the molecular pathogenesis of these tumors. An understanding of these pathways may eventually facilitate targeted therapy in patients with these tumors. (See <a href=\"#H4\" class=\"local\">'Genetic predisposition'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The Gorlin syndrome is due to mutations in the patched-1 (<em>PTCH1</em>) gene, which is a key component in the sonic hedgehog (SHH) pathway. (See <a href=\"#H5\" class=\"local\">'SHH pathway'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In Turcot syndrome, medulloblastomas are seen in conjunction with colonic polyposis. This syndrome is associated with mutations in the Wingless-related integration site (Wnt) pathway. (See <a href=\"#H6\" class=\"local\">'Wnt pathway'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Four molecular subgroups of medulloblastoma have been identified that have divergent tumor cell histology, genetics, clinical behavior, and patient outcomes: SHH, Wnt, group 3, and group 4 (<a href=\"image.htm?imageKey=NEURO%2F109467\" class=\"graphic graphic_table graphicRef109467 \">table 1</a> and <a href=\"image.htm?imageKey=NEURO%2F87770\" class=\"graphic graphic_figure graphicRef87770 \">figure 2</a>). (See <a href=\"#H4480322\" class=\"local\">'Molecular subgroups'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/1\" class=\"nounderline abstract_t\">Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002; 94:552.</a></li><li class=\"breakAll\">Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumors of the Central Nervous System, Springer-Verlag, Berlin 1993.</li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/3\" class=\"nounderline abstract_t\">Katsetos CD, Liu HM, Zacks SI. Immunohistochemical and ultrastructural observations on Homer Wright (neuroblastic) rosettes and the &quot;pale islands&quot; of human cerebellar medulloblastomas. Hum Pathol 1988; 19:1219.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/4\" class=\"nounderline abstract_t\">McLendon RE, Friedman HS, Fuchs HE, et al. Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study. Histopathology 1999; 34:154.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/5\" class=\"nounderline abstract_t\">Kozmik Z, Sure U, R&uuml;edi D, et al. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci U S A 1995; 92:5709.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/6\" class=\"nounderline abstract_t\">Yokota N, Aruga J, Takai S, et al. Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. Cancer Res 1996; 56:377.</a></li><li class=\"breakAll\">Giangaspero F, Eberhart CG, Haapasalo H, et al. Medulloblastoma. In: WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2007. p.132.</li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/8\" class=\"nounderline abstract_t\">Sure U, Berghorn WJ, Bertalanffy H, et al. Staging, scoring and grading of medulloblastoma. A postoperative prognosis predicting system based on the cases of a single institute. Acta Neurochir (Wien) 1995; 132:59.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/9\" class=\"nounderline abstract_t\">Leonard JR, Cai DX, Rivet DJ, et al. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg 2001; 95:82.</a></li><li class=\"breakAll\">Bigner DD, McLendon RE, Bruner JM. Russell and Rubenstein's Pathology of Tumors of the Nervous System, Arnold, London 1998.</li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/11\" class=\"nounderline abstract_t\">Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415:436.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/12\" class=\"nounderline abstract_t\">Evans G, Burnell L, Campbell R, et al. Congenital anomalies and genetic syndromes in 173 cases of medulloblastoma. Med Pediatr Oncol 1993; 21:433.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/13\" class=\"nounderline abstract_t\">Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991; 64:959.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/14\" class=\"nounderline abstract_t\">Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 2014; 32:4155.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/15\" class=\"nounderline abstract_t\">Goodrich LV, Milenkovi&#263; L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277:1109.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/16\" class=\"nounderline abstract_t\">Amlashi SF, Riffaud L, Brassier G, Morandi X. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer 2003; 98:618.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/17\" class=\"nounderline abstract_t\">Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332:839.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/18\" class=\"nounderline abstract_t\">Vasen HF, M&ouml;slein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57:704.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/19\" class=\"nounderline abstract_t\">Attard TM, Giglio P, Koppula S, et al. Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer 2007; 109:761.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/20\" class=\"nounderline abstract_t\">Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29:1408.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/21\" class=\"nounderline abstract_t\">Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012; 123:473.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/22\" class=\"nounderline abstract_t\">Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012; 488:49.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/23\" class=\"nounderline abstract_t\">Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29:1424.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/24\" class=\"nounderline abstract_t\">Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008; 3:e3088.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/25\" class=\"nounderline abstract_t\">Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006; 24:1924.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/26\" class=\"nounderline abstract_t\">Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012; 12:818.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/27\" class=\"nounderline abstract_t\">Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488:106.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/28\" class=\"nounderline abstract_t\">Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488:43.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/29\" class=\"nounderline abstract_t\">Jones DT, J&auml;ger N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488:100.</a></li><li class=\"breakAll\">WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.</li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/31\" class=\"nounderline abstract_t\">Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 2014; 32:886.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/32\" class=\"nounderline abstract_t\">He X, Zhang L, Chen Y, et al. The G protein &alpha; subunit G&alpha;s is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. Nat Med 2014; 20:1035.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/33\" class=\"nounderline abstract_t\">Huh JY, Kwon MJ, Seo KY, et al. Novel nonsense GNAS mutation in a 14-month-old boy with plate-like osteoma cutis and medulloblastoma. J Dermatol 2014; 41:319.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/34\" class=\"nounderline abstract_t\">Smyth I, Narang MA, Evans T, et al. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet 1999; 8:291.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/35\" class=\"nounderline abstract_t\">Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002; 31:306.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/36\" class=\"nounderline abstract_t\">Erez A, Ilan T, Amariglio N, et al. GLI3 is not mutated commonly in sporadic medulloblastomas. Cancer 2002; 95:28.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/37\" class=\"nounderline abstract_t\">Northcott PA, Buchhalter I, Morrissy AS, et al. The whole-genome landscape of medulloblastoma subtypes. Nature 2017; 547:311.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/38\" class=\"nounderline abstract_t\">Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013; 31:2927.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/39\" class=\"nounderline abstract_t\">Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148:59.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/40\" class=\"nounderline abstract_t\">Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/41\" class=\"nounderline abstract_t\">Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 2011; 71:5057.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/42\" class=\"nounderline abstract_t\">Zhao F, Ohgaki H, Xu L, et al. Molecular subgroups of adult medulloblastoma: a long-term single-institution study. Neuro Oncol 2016; 18:982.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/43\" class=\"nounderline abstract_t\">Northcott PA, Lee C, Zichner T, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 2014; 511:428.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/44\" class=\"nounderline abstract_t\">Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 2013; 14:1200.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/45\" class=\"nounderline abstract_t\">Sch&uuml;ller U, Heine VM, Mao J, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008; 14:123.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/46\" class=\"nounderline abstract_t\">Grammel D, Warmuth-Metz M, von Bueren AO, et al. Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. Acta Neuropathol 2012; 123:601.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/47\" class=\"nounderline abstract_t\">Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 2007; 4:295.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/48\" class=\"nounderline abstract_t\">Oliver TG, Wechsler-Reya RJ. Getting at the root and stem of brain tumors. Neuron 2004; 42:885.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/49\" class=\"nounderline abstract_t\">Yang ZJ, Ellis T, Markant SL, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008; 14:135.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/50\" class=\"nounderline abstract_t\">Pei Y, Moore CE, Wang J, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 2012; 21:155.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/51\" class=\"nounderline abstract_t\">Kawauchi D, Robinson G, Uziel T, et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 2012; 21:168.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/52\" class=\"nounderline abstract_t\">Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010; 468:1095.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/53\" class=\"nounderline abstract_t\">MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001; 29:143.</a></li><li><a href=\"https://www.uptodate.com/contents/histopathology-and-molecular-pathogenesis-of-medulloblastoma/abstract/54\" class=\"nounderline abstract_t\">Gilbertson RJ, Clifford SC. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 2003; 35:197.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5218 Version 19.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H8\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">HISTOPATHOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">MOLECULAR PATHOGENESIS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Genetic predisposition</a><ul><li><a href=\"#H4480307\" id=\"outline-link-H4480307\">- Gorlin syndrome</a></li><li><a href=\"#H4480314\" id=\"outline-link-H4480314\">- Turcot syndrome</a></li></ul></li><li><a href=\"#H4480322\" id=\"outline-link-H4480322\">Molecular subgroups</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">- SHH pathway</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Wnt pathway</a></li><li><a href=\"#H4480330\" id=\"outline-link-H4480330\">- Group 3</a></li><li><a href=\"#H4480338\" id=\"outline-link-H4480338\">- Group 4</a></li></ul></li></ul></li><li><a href=\"#H4480625\" id=\"outline-link-H4480625\">CELL OF ORIGIN</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">GENETIC REGULATION OF METASTASIS</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/5218|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/88305\" class=\"graphic graphic_figure\">- Histological features of medulloblastoma</a></li><li><a href=\"image.htm?imageKey=NEURO/87770\" class=\"graphic graphic_figure\">- Clinical and genomic features of medulloblastoma subgroups</a></li><li><a href=\"image.htm?imageKey=ONC/69105\" class=\"graphic graphic_figure\">- Shh Gli pathway medulloblastoma</a></li></ul></li><li><div id=\"ONC/5218|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/109467\" class=\"graphic graphic_table\">- WHO classification of medulloblastoma</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of familial adenomatous polyposis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-diagnosis-and-risk-stratification-of-medulloblastoma\" class=\"medical medical_review\">Clinical presentation, diagnosis, and risk stratification of medulloblastoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=li-fraumeni-syndrome\" class=\"medical medical_review\">Li-Fraumeni syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nevoid-basal-cell-carcinoma-syndrome\" class=\"medical medical_review\">Nevoid basal cell carcinoma syndrome</a></li></ul></div></div>","javascript":null}